ПИТАННЯ ПРО ДОЦІЛЬНІСТЬ ЗАСТОСУВАННЯ БІСФОСФОНАТІВ В СКЛАДІ НЕОАДЮВАНТНОЇ ПОЛІ ХІМІОТЕРАПІЇ У ХВОРИХ НА РМЗ
Ключові слова:
рак молочної залози, неоадювантна поліхіміотерапія, бісфосфонати
Анотація
Резюме. Метою статті було показати існуючі наукові дослідження, в яких вивчали результати сумісного застосування бісфосфонатів з хіміотерапією в комплексному лікуванні хворих на РМЗ,
Проведено аналіз результатів низки рандомізованих та ретроспективних досліджень в яких вивчали можливість синергізму в сумісному застосуванні даних групп препаратів. Ідея синергізму виникла на основі експериментальних досліджень на культерах пухлин. Також було проведено ряд досліджень адювантного застосування бісфосфонатів на фоні поліхіміотерапії, в яких було продемонстровано підсилення ефективності хіміотерапії та гормонотерапії
Встановлено, що відсутні достовірні дані на основі рандомізованих досліджень, про підвищення ефективності неоадювантної хіміотерапії разом з бісфосфонатами. Необхідність в таких дослідженнях є, і прогнозується в першу чергу отримання позитивних результатів в групі хворих на тричі негативний РМЗ, який особливо агрессивно протікає.
Посилання
1. VonMinckwitzG., UntchM.,Blohmer J.U., CostaS.D., EidtmannH, FaschingPA., Gerber В., Eiermann W., HiljriehJ., Huober J., Jackisch C, Kaufmann M., Konnecny G.E., Dencert C, Nekljudova V., Mehta K, Loibl S. Definition and impact of pathologic response on prognosis after neoadjuvant chemotherapy in various intrinsic breast can¬cer subtypes.// J Clin Oncol, 2012, May 20 30 (15): 1796-804.
2. О’Regan, R.M.; Von Roenn, J.H.; Carlson, R.W; Malik, U.; Sparano, J.A.; Staradub, V, etal. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/ cyclophosphamide) in stage III breast cancer;// Clin Breast Cancer. 2005. p. 163-8.
3. Symmans, W.F.; Peintinger, E; Hatzis, C; Rajan, R.; Kuerer, H; Valero, V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy; //J Clin Oncol.2007. p. 4414-22.
4. Stearns; V; Singh, B.; Tsangaris, T; Crawford, JG.; Novielli, A.; Ellis, MJ., etal. A prospective randomized pilot study to evaluate predictors of response in serial core biop¬sies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer; // Clin Cancer Res. 2003. p. 124-33.
5. Colleoni, M.; Viale, G.; Zahrieh, D.; Pruneri, G.; Gen- tilini, O.; Veronesi, R, etal. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment; // Clin Cancer Res. 2004. p. 6622-8.
6. Winter M.C, Syddall S.R Cross S.S, Evans C.A, Ing¬ram C.E., Jolley I.J., et al. ANZAC: A Randomized Neoaduvant Biomarker Study Investigating the Anti-Tumor Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. //Cancer Res. 2010; 70(24)
7. Kuerer, H.M.; Newman, LA.; Smith, T.L.;Ames, F.C.; Hunt, KK; Dhingra, K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy;// J Clin Oncol. 1999. p. 460-9.
8. Naidu, A.; Dechow, PC.; Spears, R.; Wright, JM.; Kessler, HR; Opperman, LA. The effects of bisphosphonates on osteoblasts in vitro; Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008. p. 5-13.
9. Kimmel D.B. Mechanism of Action, Pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.//J Dent Res 86, 2007: 1022-33.
10. Lipton A., Cook R. J., Major P, Smith M.R., Cole¬man R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12(9), 2007: 1035-1043.
11. Nagy Z. Zoledronic acid (ZOMETA): a significant improvement in the bone metastases.//Pathol Oncol Res 11, 2005: 186-87.
12. Saad F. Zoledronic acid: past, present and future roles in cancer treatment. Future Oncol 1, 2005:149-59.
13. Avile ’sA., NamboM.J., NeriN., Castae ’eda C, CletoS., et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.//Med Oncol 24, 2007: 227-30.
14. Winter MC, Holenl, Coleman RE. Exploring the anti¬tumour activity of bisphosphonates in early breast cancer.// Cancer Treat Rev. 2008 Aug;34(5):453-75.
15. Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer, 2007: S29-S35.
16. A.T. Stopeck,A. Lipton, J.J. Body, Steger G.G., Ton¬kin K., et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study.//J Clin Oncol 28, 2010: 5132-5139.
17. GnantM.FX., Mlineritsch B., Luschin-Ebengreuth G., Grampp S., Kaessmann H, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormoneresponsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.// J Clin Oncol 25, 2007: 820-8.
18. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Ga¬lanos A., et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline //Med Oncol 22, 2005: 195-201
19. Austrian Breast and Colorectal Cancer Study Group. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.// Lancet Oncol 12, 2011: 631-41.
20. T. Leal, A. Tevaarwerk, R. Love, Stewart J., Binkley
N., etal. Randomized trial of adjuvant zoledronic acid (ZA) in postmenopausal women with high-risk breast cancer. // Clin Breast Cancer , 2010: 471-476.
21. Yan T, Yin W., Zhou Q., Zhou L., Jiang Y., et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. // Eur J Cancer 48(2), 2012: 187-95.
22. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin- Ebengreuth, G.; Postlberger, S.; Menzel, C.,etal. Endocrine therapy plus zoledronic acid in premenopausal breast cancer; // N Engl J Med. 2009.p. 679-91.
23. Chlebowski RT, Col N. Bisphosphonates and breast cancer prevention.//Anticancer Agents Med Chem. 2012 Feb; 12(2): 144-50.
24. Santini D., Vincenzi B., Galluzzo S., Battistoni E, Rocci L., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and longlasting decrease of peripheral vascular endothelial growth fac¬tor levels in cancer patients.// Clin Cancer Res 13, 2007: 4482-6.
25. Rebecca A., M. Naughton, K. Trinkaus, Watson M., Ylagan L., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.// Lancet Oncol, 2010; 11: 421-28.
26. Tenta, R.; Tiblalexi, D.; Sotiriou, E.; Lembessis, P; Manoussakis, M.; Koutsilieris, M. Bone microenvironment- related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-З prostate cancer cells;// Prostate. 2004. p. 120-31.
27. AZURE Investigators Breast-Cancer Adjuvant Therapy with Zoledronic Acid.// N Engl J Med 365, 2011: 1396-1405.
28. AM. Brufsky, L.D. Bosserman, R.R. Caradonna, Haley B.B., Jones C.M., et al. Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study Зб-Month Follow-up Results.// Clin Breast Cancer , 2009:77-85.
29. H. Eidtmann, R. de Boer, N. Bundred, Llombart- CussacA., Davidson N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.// Ann Oncol 21, 2010: 2188-2194.
30. A. Llombart,A. Frassoldati, O. Paija, SleeboomH.P, Jerusalem G,. etal. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial.// Clin Breast Cancer 12(1), 2011: 40-48.
31. Ottewell, P.D.; Monkkonen, H.; Jones, M.; Lefley, D. V.; Coleman, R.E.; Holen, I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer;// J Natl Cancer Inst. 2008. p. 1167-78.
32. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Cancer. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. //2012 Jan 15;118(2):326-32. doi: 10.1002/cncr.26144. Epub 2011 May 16.
2. О’Regan, R.M.; Von Roenn, J.H.; Carlson, R.W; Malik, U.; Sparano, J.A.; Staradub, V, etal. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/ cyclophosphamide) in stage III breast cancer;// Clin Breast Cancer. 2005. p. 163-8.
3. Symmans, W.F.; Peintinger, E; Hatzis, C; Rajan, R.; Kuerer, H; Valero, V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy; //J Clin Oncol.2007. p. 4414-22.
4. Stearns; V; Singh, B.; Tsangaris, T; Crawford, JG.; Novielli, A.; Ellis, MJ., etal. A prospective randomized pilot study to evaluate predictors of response in serial core biop¬sies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer; // Clin Cancer Res. 2003. p. 124-33.
5. Colleoni, M.; Viale, G.; Zahrieh, D.; Pruneri, G.; Gen- tilini, O.; Veronesi, R, etal. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment; // Clin Cancer Res. 2004. p. 6622-8.
6. Winter M.C, Syddall S.R Cross S.S, Evans C.A, Ing¬ram C.E., Jolley I.J., et al. ANZAC: A Randomized Neoaduvant Biomarker Study Investigating the Anti-Tumor Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. //Cancer Res. 2010; 70(24)
7. Kuerer, H.M.; Newman, LA.; Smith, T.L.;Ames, F.C.; Hunt, KK; Dhingra, K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy;// J Clin Oncol. 1999. p. 460-9.
8. Naidu, A.; Dechow, PC.; Spears, R.; Wright, JM.; Kessler, HR; Opperman, LA. The effects of bisphosphonates on osteoblasts in vitro; Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008. p. 5-13.
9. Kimmel D.B. Mechanism of Action, Pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.//J Dent Res 86, 2007: 1022-33.
10. Lipton A., Cook R. J., Major P, Smith M.R., Cole¬man R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12(9), 2007: 1035-1043.
11. Nagy Z. Zoledronic acid (ZOMETA): a significant improvement in the bone metastases.//Pathol Oncol Res 11, 2005: 186-87.
12. Saad F. Zoledronic acid: past, present and future roles in cancer treatment. Future Oncol 1, 2005:149-59.
13. Avile ’sA., NamboM.J., NeriN., Castae ’eda C, CletoS., et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.//Med Oncol 24, 2007: 227-30.
14. Winter MC, Holenl, Coleman RE. Exploring the anti¬tumour activity of bisphosphonates in early breast cancer.// Cancer Treat Rev. 2008 Aug;34(5):453-75.
15. Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer, 2007: S29-S35.
16. A.T. Stopeck,A. Lipton, J.J. Body, Steger G.G., Ton¬kin K., et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study.//J Clin Oncol 28, 2010: 5132-5139.
17. GnantM.FX., Mlineritsch B., Luschin-Ebengreuth G., Grampp S., Kaessmann H, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormoneresponsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.// J Clin Oncol 25, 2007: 820-8.
18. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Ga¬lanos A., et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline //Med Oncol 22, 2005: 195-201
19. Austrian Breast and Colorectal Cancer Study Group. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.// Lancet Oncol 12, 2011: 631-41.
20. T. Leal, A. Tevaarwerk, R. Love, Stewart J., Binkley
N., etal. Randomized trial of adjuvant zoledronic acid (ZA) in postmenopausal women with high-risk breast cancer. // Clin Breast Cancer , 2010: 471-476.
21. Yan T, Yin W., Zhou Q., Zhou L., Jiang Y., et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. // Eur J Cancer 48(2), 2012: 187-95.
22. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin- Ebengreuth, G.; Postlberger, S.; Menzel, C.,etal. Endocrine therapy plus zoledronic acid in premenopausal breast cancer; // N Engl J Med. 2009.p. 679-91.
23. Chlebowski RT, Col N. Bisphosphonates and breast cancer prevention.//Anticancer Agents Med Chem. 2012 Feb; 12(2): 144-50.
24. Santini D., Vincenzi B., Galluzzo S., Battistoni E, Rocci L., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and longlasting decrease of peripheral vascular endothelial growth fac¬tor levels in cancer patients.// Clin Cancer Res 13, 2007: 4482-6.
25. Rebecca A., M. Naughton, K. Trinkaus, Watson M., Ylagan L., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.// Lancet Oncol, 2010; 11: 421-28.
26. Tenta, R.; Tiblalexi, D.; Sotiriou, E.; Lembessis, P; Manoussakis, M.; Koutsilieris, M. Bone microenvironment- related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-З prostate cancer cells;// Prostate. 2004. p. 120-31.
27. AZURE Investigators Breast-Cancer Adjuvant Therapy with Zoledronic Acid.// N Engl J Med 365, 2011: 1396-1405.
28. AM. Brufsky, L.D. Bosserman, R.R. Caradonna, Haley B.B., Jones C.M., et al. Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study Зб-Month Follow-up Results.// Clin Breast Cancer , 2009:77-85.
29. H. Eidtmann, R. de Boer, N. Bundred, Llombart- CussacA., Davidson N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.// Ann Oncol 21, 2010: 2188-2194.
30. A. Llombart,A. Frassoldati, O. Paija, SleeboomH.P, Jerusalem G,. etal. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial.// Clin Breast Cancer 12(1), 2011: 40-48.
31. Ottewell, P.D.; Monkkonen, H.; Jones, M.; Lefley, D. V.; Coleman, R.E.; Holen, I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer;// J Natl Cancer Inst. 2008. p. 1167-78.
32. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Cancer. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. //2012 Jan 15;118(2):326-32. doi: 10.1002/cncr.26144. Epub 2011 May 16.
Опубліковано
2013-09-25
Як цитувати
Чешук, В. Є. (2013). ПИТАННЯ ПРО ДОЦІЛЬНІСТЬ ЗАСТОСУВАННЯ БІСФОСФОНАТІВ В СКЛАДІ НЕОАДЮВАНТНОЇ ПОЛІ ХІМІОТЕРАПІЇ У ХВОРИХ НА РМЗ. Український науково-медичний молодіжний журнал, 3(75), 47-50. вилучено із http://mmj.nmuofficial.com/index.php/journal/article/view/750
Розділ
Медицина
